Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
- Conditions
- CholangiocarcinomaUrothelial CarcinomaCervical CancerSquamous Cell Carcinoma of Head and Neck
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 73
- Registration Number
- NCT02479178
- Locations
- 🇺🇸
Investigative Site: #20, Goodyear, Arizona, United States
🇺🇸Investigative Site: #42, Greenbrae, California, United States
🇺🇸Investigative Site: #39, Denver, Colorado, United States
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
- Conditions
- KRAS Positive Patients With Non-small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancer
- Interventions
- Drug: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 69
- Registration Number
- NCT02283320
- Locations
- 🇺🇸
Investigative Site: #51, Chandler, Arizona, United States
🇺🇸Investigative Site: #30, Goodyear, Arizona, United States
🇺🇸Investigative Site: #44, Phoenix, Arizona, United States
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT01812746
- Locations
- 🇺🇸
Investigative Site #16, Los Angeles, California, United States
🇺🇸Investigative Site #14, San Francisco, California, United States
🇺🇸Investigative Site #17, Fort Meyers, Florida, United States
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT01792479
- Locations
- 🇺🇸
Investigative Site #10, Goodyear, Arizona, United States
🇺🇸Investigative Site #04, Los Angeles, California, United States
🇺🇸Investigative Site #02, Fort Meyers, Florida, United States
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
- Conditions
- Solid TumorsMetastatic CancerCancer
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT01300533
- Locations
- 🇺🇸
Investigational Site #01, Scottsdale, Arizona, United States
🇺🇸Investigational Site #02, Greenbrae, California, United States
🇺🇸Investigational Site #04, Los Angeles, California, United States